Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
QDEL 
Quidel Corporation (QDEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: QDEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -37.66% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.30B USD | Price to earnings Ratio - | 1Y Target Price 51.14 |
Price to earnings Ratio - | 1Y Target Price 51.14 | ||
Volume (30-day avg) 814328 | Beta 0.1 | 52 Weeks Range 29.73 - 49.45 | Updated Date 04/1/2025 |
52 Weeks Range 29.73 - 49.45 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -30.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -73.74% | Operating Margin (TTM) 6.64% |
Management Effectiveness
Return on Assets (TTM) 0.65% | Return on Equity (TTM) -51.36% |
Valuation
Trailing PE - | Forward PE 13.7 | Enterprise Value 4883701615 | Price to Sales(TTM) 0.83 |
Enterprise Value 4883701615 | Price to Sales(TTM) 0.83 | ||
Enterprise Value to Revenue 1.75 | Enterprise Value to EBITDA 7.61 | Shares Outstanding 67446496 | Shares Floating 60927161 |
Shares Outstanding 67446496 | Shares Floating 60927161 | ||
Percent Insiders 1.41 | Percent Institutions 109.33 |
Analyst Ratings
Rating 3.62 | Target Price 51.14 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 3 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Quidel Corporation
Company Overview
History and Background
Quidel Corporation, now known as Ortho Clinical Diagnostics Holdings plc (OCDX), was founded in 1979. Initially focused on developing diagnostic tests for autoimmune diseases, Quidel expanded its portfolio to include rapid diagnostic tests for infectious diseases, cardiac markers, and other conditions. A major milestone was the development and commercialization of rapid influenza tests, which significantly contributed to its growth. In May 2022, Quidel acquired Ortho Clinical Diagnostics and changed its name to QuidelOrtho Corporation. In 2024, the company rebranded to Ortho Clinical Diagnostics Holdings plc.
Core Business Areas
- Point-of-Care Diagnostics: Focuses on developing and manufacturing rapid diagnostic tests for infectious diseases, cardiac markers, and other conditions, primarily used in physician's offices, hospitals, and urgent care centers.
- Molecular Diagnostics: Offers molecular diagnostic solutions for the detection of infectious diseases and other conditions. These tests are typically performed in central laboratories.
- Immunoassay Diagnostics: Ortho Clinical Diagnostics' traditional core business with a broad portfolio of immunoassays.
Leadership and Structure
The company is led by a Board of Directors and a management team. Details regarding specific roles and individuals can be found on Ortho Clinical Diagnostics' investor relations page.
Top Products and Market Share
Key Offerings
- Sofia SARS Antigen FIA: A rapid point-of-care test for the detection of SARS-CoV-2 antigen. Its market share fluctuated based on pandemic dynamics. Competitors include Abbott (ABT) with BinaxNOW, and Roche.
- QuickVue Influenza A+B Test: A rapid influenza A and B test for point-of-care settings. Competitors include Abbott (ABT) and Roche.
- Triage MeterPro: A diagnostic platform and related assays used to assist in the diagnosis and treatment of cardiovascular disease, drug overdose and toxicology. Competitors include Abbott (ABT) and Siemens Healthineers.
Market Dynamics
Industry Overview
The in-vitro diagnostics (IVD) market is characterized by technological innovation, increasing demand for rapid and accurate diagnostics, and regulatory scrutiny. Key trends include the growth of molecular diagnostics, point-of-care testing, and personalized medicine.
Positioning
Ortho Clinical Diagnostics holds a significant position in the IVD market, particularly in point-of-care and molecular diagnostics. The company's competitive advantages include its established brand, broad product portfolio, and strong distribution network.
Total Addressable Market (TAM)
The global in-vitro diagnostics market is projected to reach several hundreds of billions USD in the coming years. Ortho Clinical Diagnostics is well positioned to address a significant portion of this market with its diversified product offerings.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Broad product portfolio
- Established distribution network
- Focus on innovation
- Expertise in both point-of-care and molecular diagnostics
Weaknesses
- Dependence on infectious disease testing (fluctuates with outbreaks)
- Integration challenges post-merger (Quidel/Ortho)
- Competition from larger players with greater resources
Opportunities
- Expansion into new geographic markets
- Development of novel diagnostic tests
- Strategic partnerships and acquisitions
- Growth in emerging markets
- Increasing demand for personalized medicine
Threats
- Intense competition
- Regulatory changes
- Economic downturns
- Emergence of new infectious diseases (creates initial demand, then decline)
- Price erosion
Competitors and Market Share
Key Competitors
- ABT
- ROCHE.SW
- SI
Competitive Landscape
Ortho Clinical Diagnostics faces competition from larger and more diversified players. However, it maintains a competitive edge through its focus on innovation, strong brand recognition, and specialized product offerings.
Major Acquisitions
Ortho Clinical Diagnostics
- Year: 2022
- Acquisition Price (USD millions): 6000
- Strategic Rationale: The acquisition of Ortho Clinical Diagnostics expands Quidel's product portfolio, geographic reach, and market position in the in-vitro diagnostics market.
Growth Trajectory and Initiatives
Historical Growth: Discuss Quidel Corporation's growth trends over the past years, prior to the merger with Ortho. Since the merger, growth trajectory is now evaluated through Ortho Clinical Diagnostics' financial statements.
Future Projections: Provide projections for Ortho Clinical Diagnostics' future growth based on analyst estimates.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Ortho Clinical Diagnostics, such as product launches, acquisitions, and partnerships.
Summary
Ortho Clinical Diagnostics (formerly QuidelOrtho) is a major player in the diagnostics industry with a broad portfolio and strong brand. The company's future performance will depend on its ability to integrate its recent acquisition, innovate new products, and navigate competitive pressures. The infectious disease testing segment has been volatile, so focus on other areas like immunoassay and molecular diagnostics are likely to be key to a successful transition. It must be vigilant about competition and economic changes, and it should look for opportunities to expand. Recent acquisitions, such as Ortho Clinical Diagnostics, need to be integrated to ensure operational effectiveness.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
DHR
Danaher Corporation
DHR
Danaher Corporation
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Ortho Clinical Diagnostics Holdings plc (OCDX) Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is based on available information and is subject to change. It does not constitute financial advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quidel Corporation
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1991-02-01 | President, CEO & Director Mr. Brian J. Blaser | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6600 | Website https://www.quidelortho.com |
Full time employees 6600 | Website https://www.quidelortho.com | ||
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.